Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate cancer

Article · November 1999with13 Reads
DOI: 10.1002/(SICI)1097-0142(19991101)86:93.0.CO;2-N
The Physicians' Health Study was a randomized, double-blind, placebo-controlled trial using a 2x2 factorial design including supplementation with beta-carotene (50 mg every other day) in the primary prevention of cancer among 22,071 U.S. male physicians ages 40-84 years at randomization. Before randomization, the authors collected baseline blood specimens to determine whether any benefit was greater among or confined to those with low baseline levels of beta-carotene. Baseline blood samples were collected from 14,916 participants. These samples were assayed, according to a nested case-control design, from 1439 men subsequently diagnosed with cancer over 12 years of follow-up (631 with prostate carcinoma) and 2204 controls matched by age and smoking habits. Men in the lowest quartile for plasma beta-carotene at baseline had a marginally significant (P = 0.07) increased risk of cancer compared with those in the highest quartile (relative risk [RR] = 1.30, 95% confidence interval [CI], 0.98-1.74). Men in the lowest quartile assigned at random to beta-carotene supplementation had a possible but nonsignificant decrease in overall cancer risk (RR = 0.83, 95% CI, 0.63-1.09) compared with those assigned to placebo. This was primarily due to a significant reduction in the risk of prostate carcinoma (RR = 0.68, 95% CI, 0. 46-0.99) in this group. After the first 2 years of follow-up were excluded, the results were virtually unchanged. These prespecified subgroup analyses appeared to support the idea that beta-carotene supplementation may reduce risk of prostate carcinoma among those with low baseline levels. Further follow-up of this population will help determine whether these findings are valid.
    • β-Carotene has been extracted mainly from orange and yellow fruits and vegetables. There are many studies that correlate between the high dietary consumption of carotenoids and low risk of prostate cancer[68,69]. The inhibitory effect of β-carotene in the proliferation of human cancer cell lines (PC-3, DU 145, and LNCaP) has been determined by Williams et al.[70].
    [Show abstract] [Hide abstract] ABSTRACT: Natural products with immunomodulatory activity are widely used in treatment of many diseases including autoimmune diseases, inflammatory disorders in addition to cancer. They gained a great interest in the last decades as therapeutic agents since they provide inexpensive and less toxic products than the synthetic chemotherapeutic agents. Immunomodulators are the agents that have the ability to boost or suppress the host defense response that can be used as a prophylaxis as well as in combination with other therapeutic modalities. The anticancer activity of these immunomodulators is due to their anti-inflammatory, antioxidant, and induction of apoptosis, anti-angiogenesis, and anti-metastasis effect. These natural immunomodulators such as genistein, curcumin, and resveratrol can be used as prophylaxis against the initiation of cancer besides the inhibition of tumor growth and proliferation. Whereas, immunostimulants can elicit and activate humoral and cell-mediated immune responses against the tumor that facilitate the recognition and destruction of the already existing tumor. This review represents the recent studies on various natural immunomodulators with antitumor effects. We have focused on the relationship between their anticancer activity and immunomodulatory mechanisms. The mechanisms of action of various immunomodulators such as polyphenolic compounds, flavonoids, organosulfur compounds, capsaicin, vinca alkaloids, bromelain, betulinic acid and zerumbone, the affected cancerous cell lines in addition to the targeted molecules and transcriptional pathways have been review and critically analyzed.
    Article · Jul 2017
    • Studies suggest that antioxidants may lower a smokersÊ risk of lung cancer. [35, 36] Studies also suggest that carotenoids may help to prevent prostate, breast [36][37][38][39][40][41][42][43][44][45][46]and skin [47, 48] cancer as well as endometrial cancer. [46] Astaxanthin is another carotenoid, found in salmon, red fish, shrimp and crab, which shows anticarcinogenic effects in mouse lung and liver cancer models.
    [Show abstract] [Hide abstract] ABSTRACT: This article has been made to review some medicinal plants used for the treating cancer disease. The plant sources of India are likely to provide effective anticancer agents. Herbs have a vital role in the prevention and treatment of cancer. Examples are provided in this review of promising bioactive compounds obtained from various plants with medicinal and other therapeutic uses. The photochemical exploration of these herbs has contributed to some extent in this race for the discovery of new anticancer drugs. In recent years owing to the fear of side effects people prefer to use of natural plant products for cancer treatment. This review also helps to summarize the diverse methodologies and various ways to evaluate the potential natural compounds having anticancer activity. Although drug discovery from medicinal plants continues to provide an important source of new drug leads, numerous challenges are encountered including the procurement of plant materials and their selection.
    Full-text · Article · Mar 2014 · BJU International
    • However, a subgroup analysis showed that men in the lowest quartile for plasma b-carotene had a decrease, although not statistically significant, in overall cancer risk (RR, 0.83; 95% CI, 0.63–1.09) compared with those assigned to placebo (Cook et al., 1999). No protective effect was found for b-carotene on skin cancer (RR, 0.98; 95% CI, 0.92–1.05)
    [Show abstract] [Hide abstract] ABSTRACT: It has been almost 30 years since Doll and Peto suggested that most of the differences in cancer rates could be attributed to the environment and behavioral factors including diet. Since then epidemiological studies have reported that individuals consuming large amounts of fruits and vegetables have a reduced risk of cancer. From this evidence, large randomized trials of long duration were designed to test the hypothesis that some micronutrients contained in plant foods decrease cancer risk. Despite the promising experimental and epidemiological data, most randomized controlled trials failed to confirm a protective role for single or combined elements in cancer prevention. The results from randomized trials of micronutrients for cancer prevention have been mixed. Some trials did not demonstrate chemopreventive efficacy for their primary endpoints but showed statistically significant reductions in secondary outcomes, whereas others showed unexpected harmful effects. On the basis of these findings and reflections of what went wrong it is important to find alternative approaches to move forwards in cancer prevention. Clearly, the evidence is not encouraging for further preventive trials on cancer in healthy populations. However, if we identify high-risk individuals using models that include genetic polymorphisms, or in the future, MicroRNA profiles, prevention trials could be designed to target only these groups.
    Article · Jun 2011
    • Studies suggest that antioxidants may lower a smokers' risk of lung cancer [26, 27]. Studies also suggest that carotenoids may help to prevent prostate, breast2728293031323334353637, and skin [38, 39] cancer as well as endometrial cancer [37]. Astaxanthin (Figure 1D) is another carotenoid, found in salmon, red fish, shrimp and crab, which shows anti-carcinogenic effects in mouse lung and liver cancer models.
    [Show abstract] [Hide abstract] ABSTRACT: Although tremendous progress has been made in basic cancer biology and in the development of novel cancer treatments, cancer remains a leading cause of death in the world. The etiopathogenesis of cancer is complex. Besides genetic predisposition, known environmental factors associated with cancer are: diet, lifestyle, and environmental toxins. Toxicity of drugs and eventual relapse of cancers contribute to high cancer death rates. Current therapeutic interventions for cancer- surgery, chemotherapy, radiotherapy, thermotherapy, etc. are far from being curative for many forms of cancer. Chemotherapy, in particular, though the most commonly used cancer treatment, is usually associated with side effects with varying degrees of severity. The purpose of this brief review is to assemble current literature on some crude drugs and to focus on their beneficial roles and drug targets in cancer therapy and chemo-prevention. Although their pharmacological mechanisms and biochemical roles in cancer biology and tumor chemo-prevention are not fully understood, crude drugs are believed to have nutriceutical effects upon cancer patients.
    Full-text · Article · Jan 2011
    • These studies have found no relationship between supplementation and prostate cancer among generally nonsmoking study populations [18]. In addition, the PhysicianU s Health Study reported a 32 percent reduction in prostate cancer incidence for those men receiving S -carotene supplementation who were in the lowest quartile of plasma betacarotene when the study began [12]. This fact lends support to the hypothesis that S -carotene may be protective at the doses available from dietary intake alone rather than from megadoses in supplement form [19].
    [Show abstract] [Hide abstract] ABSTRACT: The purpose of this systematic review was to investigate the association between dietary intake of citrus fruits and prostate cancer risk. Authors searched electronic databases and the reference lists of publications of diet and prostate cancer studies until August 2007. All of the epidemiological studies that obtained individual data on dietary intake of citrus fruits and presented risk estimates of the association between intake of citrus fruits and risk of prostate cancer were identified and included. Using general variance-based methods, study-specific odds ratios (OR)/ relative risk (RR) and associated confidence interval (CI)/ standard error (SE) for highest versus lowest intake of citrus fruits level were extracted from each paper. Eleven articles including six case-control studies, one nested case-control study and four cohort studies, proved eligible. Overall summary OR using random effect model did not show an association in risk of prostate cancer with intake of citrus fruits (summary OR=1.03, 95% CI=0.89-1.19) with large heterogeneity across studies that we were unable to explain (I(2)=67.88%). The summary ORs in case-control studies and cohort studies were 1.10 (95% CI=0.97-1.22) and 1.05 (95% CI=0.96-1.14), respectively. Pooled results from observational studies did not show an association between intake of citrus fruits and the risk of prostate cancer, although results vary substantially across studies.
    Full-text · Article · Jun 2008
    • association (Shibata et al. 1992, Giovannucci et al. 1995). In one intervention study β-carotene supplementation seemed to reduce prostate cancer incidence in subjects with low baseline plasma β-carotene levels (RR = 0.68, 95% CI 0.46-0.99), but to increase prostate cancer incidence in subjects with high baseline levels (RR=1.33, 95% CI 0.91-1.96; Cook et al. 1999). Other vitamins investigated include C, D and E. Vitamin C is a scavenger of reactive oxygen species and free radicals (Yu et al. 1994). Maramag et al. (1997) showed that vitamin C inhibits cell proliferation in prostate cancer cell lines. However, data from prospective cohort studies show no consistent effect (Shibata et al. 1992, Gio
    Article · Jan 2006
Show more
July 2003 · American Journal of Clinical Nutrition · Impact Factor: 6.77
    Adult body size and composition (ABSC) measures are associated with work capacity and productivity, reproductive performance, and chronic disease risk. Growth failure in early childhood may have important long-term consequences through its influence on ABSC. We assessed associations between prenatal and postnatal growth (0-2 y of age) and ABSC. We included 267 singletons from a prospective... [Show full abstract]
    March 2012 · Cancer Epidemiology Biomarkers & Prevention · Impact Factor: 4.13
      The evidence about nitrosamines and heme iron intake and cancer risk is limited, despite the biologic plausibility of the hypothesis that these factors might increase cancer risk. We investigated the association between dietary nitrosamines and heme iron and the risk of prostate cancer among participants of European Prospective Investigation into Cancer and Nutrition (EPIC). Data on food... [Show full abstract]
      April 2012 · Journal of Cancer Epidemiology
        Comorbidity influences screening practice, treatment choice, quality of life, and survival. The presence of comorbidities and medication use could place patients at greater risks of adverse effects from certain interventions. We conducted a longitudinal cohort study in the General Practice Research Database to better understand comorbidities and medication use in men with or at risk of... [Show full abstract]
        July 2012 · Cancer Causes and Control · Impact Factor: 2.74
          Data from prospective epidemiological studies in Asian populations and from experimental studies in animals and cell lines suggest a possible protective association between dietary isoflavones and the development of prostate cancer. We examined the association between circulating concentrations of genistein and prostate cancer risk in a case-control study nested in the European Prospective... [Show full abstract]
          Discover more